339 related articles for article (PubMed ID: 21785355)
1. Adjuvant therapy with bone-targeted agents.
Wilson C; Coleman RE
Curr Opin Support Palliat Care; 2011 Sep; 5(3):241-50. PubMed ID: 21785355
[TBL] [Abstract][Full Text] [Related]
2. [Encounter of cancer cells with bone. Cancer treatment-induced bone loss : CTIBL].
Takahashi S
Clin Calcium; 2011 Mar; 21(3):447-53. PubMed ID: 21358067
[TBL] [Abstract][Full Text] [Related]
3. Denosumab and the current status of bone-modifying drugs in breast cancer.
Lee BL; Higgins MJ; Goss PE
Acta Oncol; 2012 Feb; 51(2):157-67. PubMed ID: 22150116
[TBL] [Abstract][Full Text] [Related]
4. Antiresorptive therapies in oncology and their effects on cancer progression.
Bundred N
Cancer Treat Rev; 2012 Oct; 38(6):776-86. PubMed ID: 22370427
[TBL] [Abstract][Full Text] [Related]
5. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
Brufsky A
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
[TBL] [Abstract][Full Text] [Related]
6. Denosumab: benefits of RANK ligand inhibition in cancer patients.
Lipton A; Jacobs I
Curr Opin Support Palliat Care; 2011 Sep; 5(3):258-64. PubMed ID: 21826000
[TBL] [Abstract][Full Text] [Related]
7. [ RANKL antibody for treatment of cancer treatment-induced bone loss (CTIBL)].
Takahashi S
Clin Calcium; 2011 Aug; 21(8):1239-47. PubMed ID: 21814031
[TBL] [Abstract][Full Text] [Related]
8. The role of bisphosphonates in the adjuvant setting for breast cancer.
Reeder JG; Brufsky AM
Oncology (Williston Park); 2010 May; 24(6):462-7, 475. PubMed ID: 20568587
[TBL] [Abstract][Full Text] [Related]
9. Cancer treatment-induced bone loss: pathophysiology and clinical perspectives.
Brufsky AM
Oncologist; 2008 Feb; 13(2):187-95. PubMed ID: 18305064
[TBL] [Abstract][Full Text] [Related]
10. New results from the use of bisphosphonates in cancer patients.
Coleman R; Gnant M
Curr Opin Support Palliat Care; 2009 Sep; 3(3):213-8. PubMed ID: 19561507
[TBL] [Abstract][Full Text] [Related]
11. Maintaining bone density in patients undergoing treatment for breast cancer: is there an adjuvant benefit?
Gnant M; Dubsky P; Fitzal F; Blaha P; Schoppmann S; Steger G; Marth C; Samonigg H; Hüttner K; Fohler H; Ruecklinger E; Jakesz R; Greil R;
Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S18-27. PubMed ID: 19561003
[TBL] [Abstract][Full Text] [Related]
12. Effects of bone-targeted agents on cancer progression and mortality.
Coleman R; Gnant M; Morgan G; Clezardin P
J Natl Cancer Inst; 2012 Jul; 104(14):1059-67. PubMed ID: 22752060
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.
Fizazi K; Lipton A; Mariette X; Body JJ; Rahim Y; Gralow JR; Gao G; Wu L; Sohn W; Jun S
J Clin Oncol; 2009 Apr; 27(10):1564-71. PubMed ID: 19237632
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates in the adjuvant treatment of breast cancer.
Winter MC; Coleman RE
Clin Oncol (R Coll Radiol); 2013 Feb; 25(2):135-45. PubMed ID: 23207072
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant bone-targeted therapy to prevent metastasis: lessons from the AZURE study.
Coleman RE
Curr Opin Support Palliat Care; 2012 Sep; 6(3):322-9. PubMed ID: 22801464
[TBL] [Abstract][Full Text] [Related]
16. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial.
Fizazi K; Bosserman L; Gao G; Skacel T; Markus R
J Urol; 2009 Aug; 182(2):509-15; discussion 515-6. PubMed ID: 19524963
[TBL] [Abstract][Full Text] [Related]
17. New developments for treatment and prevention of bone metastases.
Body JJ
Curr Opin Oncol; 2011 Jul; 23(4):338-42. PubMed ID: 21519257
[TBL] [Abstract][Full Text] [Related]
18. Should bisphosphonates be utilized in the adjuvant setting for breast cancer?
Lipton A
Breast Cancer Res Treat; 2010 Aug; 122(3):627-36. PubMed ID: 20490653
[TBL] [Abstract][Full Text] [Related]
19. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial.
Fizazi K; Bosserman L; Gao G; Skacel T; Markus R
J Urol; 2013 Jan; 189(1 Suppl):S51-7; discussion S57-8. PubMed ID: 23234632
[TBL] [Abstract][Full Text] [Related]
20. Cancer treatment-induced bone loss in breast and prostate cancer.
Saad F; Adachi JD; Brown JP; Canning LA; Gelmon KA; Josse RG; Pritchard KI
J Clin Oncol; 2008 Nov; 26(33):5465-76. PubMed ID: 18955443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
